| components_charts_RevenueChart_14 | Capricor Therapeutics components_charts_RevenueChart_8 | Capricor Therapeutics components_charts_RevenueChart_10 | Capricor Therapeutics components_charts_RevenueChart_9 |
|---|---|---|---|
| 2029e | 349.48 number_format_mio undefined | 0 undefined | -10.06 number_format_mio undefined |
| 2028e | 255.65 number_format_mio undefined | 136.76 number_format_mio undefined | -21.41 number_format_mio undefined |
| 2027e | 192.31 number_format_mio undefined | 80.24 number_format_mio undefined | 1.95 number_format_mio undefined |
| 2026e | 124.91 number_format_mio undefined | 32.18 number_format_mio undefined | 25.23 number_format_mio undefined |
| 2025e | 121.74 number_format_mio undefined | -24.53 number_format_mio undefined | 3.16 number_format_mio undefined |
| 2024e | 29.1 number_format_mio undefined | -39.69 number_format_mio undefined | -31.23 number_format_mio undefined |
| 2023 | 25.18 number_format_mio undefined | -5.41 number_format_mio undefined | -22.29 number_format_mio undefined |
| 2022 | 2.55 number_format_mio undefined | -22.23 number_format_mio undefined | -29.02 number_format_mio undefined |
| 2021 | 240,000 undefined | -15.84 number_format_mio undefined | -20.02 number_format_mio undefined |
| 2020 | 310,000 undefined | -10.29 number_format_mio undefined | -13.66 number_format_mio undefined |
| 2019 | 1.01 number_format_mio undefined | -7.73 number_format_mio undefined | -7.64 number_format_mio undefined |
| 2018 | 1.67 number_format_mio undefined | -15.33 number_format_mio undefined | -15.19 number_format_mio undefined |
| 2017 | 2.67 number_format_mio undefined | -12.86 number_format_mio undefined | 2.43 number_format_mio undefined |
| 2016 | 4 number_format_mio undefined | -16.98 number_format_mio undefined | -18.81 number_format_mio undefined |
| 2015 | 5.52 number_format_mio undefined | -12.61 number_format_mio undefined | -12.86 number_format_mio undefined |
| 2014 | 4.79 number_format_mio undefined | -6.02 number_format_mio undefined | -6.22 number_format_mio undefined |
| 2013 | 500,000 undefined | -6.9 number_format_mio undefined | -8.89 number_format_mio undefined |
| 2012 | 1.9 number_format_mio undefined | -2.1 number_format_mio undefined | -2.07 number_format_mio undefined |
| 2011 | 1.35 number_format_mio undefined | -4.9 number_format_mio undefined | -4.88 number_format_mio undefined |
| 2010 | 0 undefined | -6.29 number_format_mio undefined | -6.03 number_format_mio undefined |
| 2009 | 0 undefined | -7.88 number_format_mio undefined | -7.87 number_format_mio undefined |
| 2008 | 0 undefined | -13.4 number_format_mio undefined | -13.13 number_format_mio undefined |
| 2007 | 100,000 undefined | -9.5 number_format_mio undefined | -10.3 number_format_mio undefined |
| 2006 | 380,000 undefined | -2.5 number_format_mio undefined | -2.58 number_format_mio undefined |
| 2005 | 0 undefined | -20,000 undefined | -20,000 undefined |
| 2004 | 0 undefined | -20,000 undefined | -20,000 undefined |
| components_charts_RevenueChart_8 | components_charts_RevenueChart_10 | components_charts_RevenueChart_9 | |
|---|---|---|---|
| 2004 | 0 USD | -20,000 USD | -20,000 USD |
| 2005 | 0 USD | -20,000 USD | -20,000 USD |
| 2006 | 380,000 USD | -2.5 number_format_mio USD | -2.58 number_format_mio USD |
| 2007 | 100,000 USD | -9.5 number_format_mio USD | -10.3 number_format_mio USD |
| 2008 | 0 USD | -13.4 number_format_mio USD | -13.13 number_format_mio USD |
| 2009 | 0 USD | -7.88 number_format_mio USD | -7.87 number_format_mio USD |
| 2010 | 0 USD | -6.29 number_format_mio USD | -6.03 number_format_mio USD |
| 2011 | 1.35 number_format_mio USD | -4.9 number_format_mio USD | -4.88 number_format_mio USD |
| 2012 | 1.9 number_format_mio USD | -2.1 number_format_mio USD | -2.07 number_format_mio USD |
| 2013 | 500,000 USD | -6.9 number_format_mio USD | -8.89 number_format_mio USD |
| 2014 | 4.79 number_format_mio USD | -6.02 number_format_mio USD | -6.22 number_format_mio USD |
| 2015 | 5.52 number_format_mio USD | -12.61 number_format_mio USD | -12.86 number_format_mio USD |
| 2016 | 4 number_format_mio USD | -16.98 number_format_mio USD | -18.81 number_format_mio USD |
| 2017 | 2.67 number_format_mio USD | -12.86 number_format_mio USD | 2.43 number_format_mio USD |
| 2018 | 1.67 number_format_mio USD | -15.33 number_format_mio USD | -15.19 number_format_mio USD |
| 2019 | 1.01 number_format_mio USD | -7.73 number_format_mio USD | -7.64 number_format_mio USD |
| 2020 | 310,000 USD | -10.29 number_format_mio USD | -13.66 number_format_mio USD |
| 2021 | 240,000 USD | -15.84 number_format_mio USD | -20.02 number_format_mio USD |
| 2022 | 2.55 number_format_mio USD | -22.23 number_format_mio USD | -29.02 number_format_mio USD |
| 2023 | 25.18 number_format_mio USD | -5.41 number_format_mio USD | -22.29 number_format_mio USD |
| 2024e | 29.1 number_format_mio USD | -39.69 number_format_mio USD | -31.23 number_format_mio USD |
| 2025e | 121.74 number_format_mio USD | -24.53 number_format_mio USD | 3.16 number_format_mio USD |
| 2026e | 124.91 number_format_mio USD | 32.18 number_format_mio USD | 25.23 number_format_mio USD |
| 2027e | 192.31 number_format_mio USD | 80.24 number_format_mio USD | 1.95 number_format_mio USD |
| 2028e | 255.65 number_format_mio USD | 136.76 number_format_mio USD | -21.41 number_format_mio USD |
| 2029e | 349.48 number_format_mio USD | 0 USD | -10.06 number_format_mio USD |
components_StockTable_20
components_StockTable_21
components_StockTable_17
components_StockTable_18
components_StockTable_19
| Capricor Therapeutics components_charts_MarginsChart_15 | Capricor Therapeutics components_charts_MarginsChart_16 | Capricor Therapeutics components_charts_MarginsChart_17 | Capricor Therapeutics components_charts_MarginsChart_16 |
|---|---|---|---|
| 2029e | 0 % | 0 % | -2.88 % |
| 2028e | 0 % | 53.5 % | -8.38 % |
| 2027e | 0 % | 41.73 % | 1.01 % |
| 2026e | 0 % | 25.76 % | 20.2 % |
| 2025e | 0 % | -20.15 % | 2.6 % |
| 2024e | 0 % | -136.36 % | -107.3 % |
| 2023 | 0 % | -21.49 % | -88.52 % |
| 2022 | 0 % | -871.76 % | -1,138.04 % |
| 2021 | 0 % | -6,600 % | -8,341.67 % |
| 2020 | 0 % | -3,319.35 % | -4,406.45 % |
| 2019 | 0 % | -765.35 % | -756.44 % |
| 2018 | 0 % | -917.96 % | -909.58 % |
| 2017 | 0 % | -481.65 % | 91.01 % |
| 2016 | 0 % | -424.5 % | -470.25 % |
| 2015 | 0 % | -228.44 % | -232.97 % |
| 2014 | 0 % | -125.68 % | -129.85 % |
| 2013 | 0 % | -1,380 % | -1,778 % |
| 2012 | 0 % | -110.53 % | -108.95 % |
| 2011 | 0 % | -362.96 % | -361.48 % |
| 2010 | 0 % | 0 % | 0 % |
| 2009 | 0 % | 0 % | 0 % |
| 2008 | 0 % | 0 % | 0 % |
| 2007 | 0 % | -9,500 % | -10,300 % |
| 2006 | 0 % | -657.89 % | -678.95 % |
| 2005 | 0 % | 0 % | 0 % |
| 2004 | 0 % | 0 % | 0 % |
| components_charts_MarginsChart_15 | components_charts_MarginsChart_17 | components_charts_MarginsChart_16 | |
|---|---|---|---|
| 2004 | 0 % | 0 % | 0 % |
| 2005 | 0 % | 0 % | 0 % |
| 2006 | 0 % | -657.89 % | -678.95 % |
| 2007 | 0 % | -9,500 % | -10,300 % |
| 2008 | 0 % | 0 % | 0 % |
| 2009 | 0 % | 0 % | 0 % |
| 2010 | 0 % | 0 % | 0 % |
| 2011 | 0 % | -362.96 % | -361.48 % |
| 2012 | 0 % | -110.53 % | -108.95 % |
| 2013 | 0 % | -1,380 % | -1,778 % |
| 2014 | 0 % | -125.68 % | -129.85 % |
| 2015 | 0 % | -228.44 % | -232.97 % |
| 2016 | 0 % | -424.5 % | -470.25 % |
| 2017 | 0 % | -481.65 % | 91.01 % |
| 2018 | 0 % | -917.96 % | -909.58 % |
| 2019 | 0 % | -765.35 % | -756.44 % |
| 2020 | 0 % | -3,319.35 % | -4,406.45 % |
| 2021 | 0 % | -6,600 % | -8,341.67 % |
| 2022 | 0 % | -871.76 % | -1,138.04 % |
| 2023 | 0 % | -21.49 % | -88.52 % |
| 2024e | 0 % | -136.36 % | -107.3 % |
| 2025e | 0 % | -20.15 % | 2.6 % |
| 2026e | 0 % | 25.76 % | 20.2 % |
| 2027e | 0 % | 41.73 % | 1.01 % |
| 2028e | 0 % | 53.5 % | -8.38 % |
| 2029e | 0 % | 0 % | -2.88 % |
| components_charts_RevenuePerShareChart_17 | Capricor Therapeutics components_charts_RevenuePerShareChart_10 | Capricor Therapeutics components_charts_RevenuePerShareChart_12 | Capricor Therapeutics components_charts_RevenuePerShareChart_11 |
|---|---|---|---|
| 2029e | 10.99 undefined | 0 undefined | -0.32 undefined |
| 2028e | 8.04 undefined | 0 undefined | -0.67 undefined |
| 2027e | 6.05 undefined | 0 undefined | 0.06 undefined |
| 2026e | 3.93 undefined | 0 undefined | 0.79 undefined |
| 2025e | 3.83 undefined | 0 undefined | 0.1 undefined |
| 2024e | 0.91 undefined | 0 undefined | -0.98 undefined |
| 2023 | 0.94 undefined | -0.2 undefined | -0.83 undefined |
| 2022 | 0.1 undefined | -0.91 undefined | -1.18 undefined |
| 2021 | 0.01 undefined | -0.69 undefined | -0.87 undefined |
| 2020 | 0.02 undefined | -0.66 undefined | -0.88 undefined |
| 2019 | 0.27 undefined | -2.08 undefined | -2.06 undefined |
| 2018 | 0.57 undefined | -5.21 undefined | -5.17 undefined |
| 2017 | 1 undefined | -4.8 undefined | 0.91 undefined |
| 2016 | 2.15 undefined | -9.13 undefined | -10.11 undefined |
| 2015 | 3.47 undefined | -7.93 undefined | -8.09 undefined |
| 2014 | 4.09 undefined | -5.15 undefined | -5.32 undefined |
| 2013 | 0.48 undefined | -6.57 undefined | -8.47 undefined |
| 2012 | 1.92 undefined | -2.12 undefined | -2.09 undefined |
| 2011 | 19.29 undefined | -70 undefined | -69.71 undefined |
| 2010 | 0 undefined | -104.83 undefined | -100.5 undefined |
| 2009 | 0 undefined | -157.6 undefined | -157.4 undefined |
| 2008 | 0 undefined | -268 undefined | -262.6 undefined |
| 2007 | 3.33 undefined | -316.67 undefined | -343.33 undefined |
| 2006 | 12.67 undefined | -83.33 undefined | -86 undefined |
| 2005 | 0 undefined | -1 undefined | -1 undefined |
| 2004 | 0 undefined | -1 undefined | -1 undefined |
| components_charts_RevenuePerShareChart_10 | components_charts_RevenuePerShareChart_12 | components_charts_RevenuePerShareChart_11 | |
|---|---|---|---|
| 2004 | 0 USD | -1 USD | -1 USD |
| 2005 | 0 USD | -1 USD | -1 USD |
| 2006 | 12.67 USD | -83.33 USD | -86 USD |
| 2007 | 3.33 USD | -316.67 USD | -343.33 USD |
| 2008 | 0 USD | -268 USD | -262.6 USD |
| 2009 | 0 USD | -157.6 USD | -157.4 USD |
| 2010 | 0 USD | -104.83 USD | -100.5 USD |
| 2011 | 19.29 USD | -70 USD | -69.71 USD |
| 2012 | 1.92 USD | -2.12 USD | -2.09 USD |
| 2013 | 0.48 USD | -6.57 USD | -8.47 USD |
| 2014 | 4.09 USD | -5.15 USD | -5.32 USD |
| 2015 | 3.47 USD | -7.93 USD | -8.09 USD |
| 2016 | 2.15 USD | -9.13 USD | -10.11 USD |
| 2017 | 1 USD | -4.8 USD | 0.91 USD |
| 2018 | 0.57 USD | -5.21 USD | -5.17 USD |
| 2019 | 0.27 USD | -2.08 USD | -2.06 USD |
| 2020 | 0.02 USD | -0.66 USD | -0.88 USD |
| 2021 | 0.01 USD | -0.69 USD | -0.87 USD |
| 2022 | 0.1 USD | -0.91 USD | -1.18 USD |
| 2023 | 0.94 USD | -0.2 USD | -0.83 USD |
| 2024e | 0.91 USD | 0 USD | -0.98 USD |
| 2025e | 3.83 USD | 0 USD | 0.1 USD |
| 2026e | 3.93 USD | 0 USD | 0.79 USD |
| 2027e | 6.05 USD | 0 USD | 0.06 USD |
| 2028e | 8.04 USD | 0 USD | -0.67 USD |
| 2029e | 10.99 USD | 0 USD | -0.32 USD |
| components_EarningsSuprises__1 | components_EarningsSuprises__2 | components_EarningsSuprises__3 | components_EarningsSuprises__4 |
|---|---|---|---|
| 3/31/2024 | -0.12 | -0.31 (-168.17 %) | 2024 Q1 |
| 12/31/2023 | -0.09 | -0.02 (78.21 %) | 2023 Q4 |
| 9/30/2023 | -0.3 | -0.25 (15.48 %) | 2023 Q3 |
| 6/30/2023 | -0.36 | -0.29 (18.77 %) | 2023 Q2 |
| 3/31/2023 | -0.33 | -0.31 (5.02 %) | 2023 Q1 |
| 12/31/2022 | -0.34 | -0.31 (9.28 %) | 2022 Q4 |
| 9/30/2022 | -0.3 | -0.26 (13.1 %) | 2022 Q3 |
| 6/30/2022 | -0.26 | -0.29 (-11.5 %) | 2022 Q2 |
| 12/31/2021 | -0.19 | -0.26 (-34.16 %) | 2021 Q4 |
| 9/30/2021 | -0.22 | -0.17 (24.24 %) | 2021 Q3 |
components_ESGRating_7
components_OwnershipTable__4 | components_OwnershipTable__0 | components_OwnershipTable__1 | components_OwnershipTable__2 | components_OwnershipTable__3 |
|---|---|---|---|---|
| 6.75 % | Nippon Shinyaku Co Ltd | 2,145,922 | 2,145,922 | 10/3/2023 |
| 3.66 % | The Vanguard Group, Inc. | 1,165,404 | 13,086 | 12/31/2023 |
| 2.86 % | Woodline Partners LP | 909,542 | 909,542 | 12/31/2023 |
| 1.12 % | BlackRock Institutional Trust Company, N.A. | 355,730 | 1,099 | 12/31/2023 |
| 0.99 % | Geode Capital Management, L.L.C. | 316,198 | 47,570 | 12/31/2023 |
| 0.63 % | Marban (Linda) | 199,524 | -177,855 | 3/18/2024 |
| 0.47 % | Susquehanna International Group, LLP | 149,115 | 19,840 | 12/31/2023 |
| 0.46 % | Renaissance Technologies LLC | 146,321 | 103,700 | 12/31/2023 |
| 0.42 % | Litvack (Frank) | 133,269 | 0 | 3/18/2024 |
| 0.37 % | Osaic Holdings, Inc. | 116,550 | 110,550 | 12/31/2023 |
Capricor Therapeutics Inc的价值观和企业理念是为了推动创新的生物医药技术，改善世界各地患者的生活质量。公司专注于开发基于干细胞治疗方法的创新治疗方案，致力于治疗心脏病和肌肉萎缩症等罕见疾病。Capricor Therapeutics Inc相信通过紧密合作、多学科团队合作和优质研究成果，可以为全球患者提供更好的治疗选择。公司注重科学严谨性和透明度，致力于符合最高的伦理和合规标准，以确保产品的安全性和疗效。作为一家专注于生物医药创新的公司，Capricor Therapeutics Inc致力于为医疗行业的发展作出贡献，为患者提供更好的未来。
Capricor Therapeutics Inc是一家生物技术公司，总部位于美国加利福尼亚州洛杉矶。该公司主要在美国开展业务，而且其产品和研究项目也主要集中在美国境内。目前，Capricor Therapeutics Inc在全球范围内没有其他国家和地区的分支机构或业务存在。
Capricor Therapeutics Inc（Capricor Therapeutics股票代码：CAPR）已经达到了以下重要里程碑： 1. Capricor Therapeutics成立于2005年，是一家专注于心血管疾病治疗的生物制药公司。 2. 公司的重要里程碑之一是成功开发了一种名为Cenderitide的心血管疾病治疗药物。Cenderitide被设计用于治疗严重心力衰竭患者，并通过多项临床试验取得了积极的结果。 3. 另一个重要里程碑是Capricor Therapeutics正在开展针对肌萎缩性脊髓侧索硬化症（ALS）的研究，并展示出潜在的治疗效果。该研究旨在使用公司的核心技术平台CDCs改善ALS患者的生存期和生活质量。 4. Capricor Therapeutics还在加快开发其他治疗心血管和肌肉疾病的创新药物，以满足患者的需求。 以上是Capricor Therapeutics Inc的重要里程碑，展示了该公司在心血管和肌肉疾病领域的努力和成就。
Capricor Therapeutics Inc是一家生物医药公司，总部位于美国加利福尼亚州洛杉矶。该公司专注于开发创新的细胞治疗和再生医学解决方案，旨在治疗心血管疾病和其他严重疾病。Capricor Therapeutics Inc致力于通过干细胞疗法和新型先导药物开发，改善患者的生活质量和预后。该公司的研发项目包括了基于干细胞疗法的心肌梗死和心力衰竭的治疗，以及用于Duchenne肌营养不良症（Duchenne Muscular Dystrophy）的新型疗法。Capricor Therapeutics Inc的使命是为全球患者提供创新、安全和高效的医疗解决方案，并为股东和利益相关方创造可持续的价值。
Capricor Therapeutics Inc（凯匹骆治疗公司）在市场上的主要竞争对手是Mesoblast Limited（美索布朗公司）。
Capricor Therapeutics Inc是一家专注于生物医药领域的公司。该公司研发和商业化创新的细胞治疗产品，主要针对心脏疾病和其他罕见疾病。Capricor Therapeutics Inc利用其核心技术平台开发具有潜力的干细胞治疗方法，以改善患者的生活质量，并满足医疗领域的严重需求。通过持续的研究和开发，该公司力求为全球患者提供更安全、更有效的治疗选择。
Capricor Therapeutics Inc（Capricor Therapeutics股票代码：CAPR）的商业模式是通过开发创新的细胞疗法和生物制剂，致力于治疗罕见疾病和心脏疾病。该公司专注于与干细胞和外泌体相关的治疗方法，为病患提供希望和改善生活质量的治疗选择。Capricor Therapeutics的目标是通过再生药物的研究和开发帮助那些缺少其他有效治疗方法的患者。该公司不断努力推动细胞疗法的创新，同时与学术界和医疗专业人士合作，以加速创新的治疗方法进入市场。以Capricor Therapeutics为名的公司专注于推动医学的进步，并提供更好的治疗选择来改善患者的生活。 Note: The answer has been optimized for SEO, with the company name mentioned throughout the response.
pages_aktie_[isin]__12
pages_aktie_[isin]__15
pages_aktie_[isin]__18
pages_aktie_[isin]__21
pages_aktie_[isin]__24
pages_aktie_[isin]__27
pages_aktie_[isin]__30
pages_aktie_[isin]__34
pages_aktie_[isin]__36
pages_aktie_[isin]__38
pages_aktie_[isin]__40
pages_aktie_[isin]_[key]_index_1
pages_aktie_[isin]_[key]_index_3
pages_aktie_[isin]_[key]_index_5
pages_aktie_[isin]_[key]_index_7
pages_aktie_[isin]_[key]_index_9
pages_aktie_[isin]_[key]_index_14
pages_aktie_[isin]_[key]_index_15
pages_aktie_[isin]_[key]_index_18
pages_aktie_[isin]_[key]_index_20
pages_aktie_[isin]_[key]_index_22
components_Profile_KeyStats__40
components_Profile_KeyStats__33
components_Profile_KeyStats__36
components_Profile_KeyStats__37| components_Profile_Tickers_1 | Capricor Therapeutics components_Profile_Tickers_2 |
|---|---|
| COMPONENTS_PROFILE_TICKERS_23 | 4LN2.F |
| NASDAQ | CAPR |
| Capricor Therapeutics components_Profile_Tickers_2 | Capricor Therapeutics FIGI |
|---|---|
| CAPR:US | BBG000DZMK99 |
| CAPR:UA | BBG000DZML24 |
| CAPR:UC | BBG000DZMLF0 |
| CAPR:UN | BBG000DZMMQ6 |
| CAPR:UP | BBG000DZMMY7 |
| CAPR:UB | BBG000DZMPS7 |
| CAPR:UM | BBG000DZMRM9 |
| CAPR:UX | BBG000DZMRX7 |
| CAPR:UR | BBG000DZMS38 |
| CAPR:UD | BBG000DZMVV0 |
| CAPR:UF | BBG000DZMY53 |
| CAPR:VY | BBG000DZMYP1 |
| CAPR:VJ | BBG000DZMZF9 |
| CAPR:VK | BBG000DZMZR6 |
| CAPR:VF | BBG00DJFZK04 |
| 4LN2:GR | BBG00H66HMD1 |
| 4LN2:GF | BBG00H66HMF9 |
| 4LN2:GS | BBG00H66HMJ5 |
| 4LN2:GB | BBG00H66HML2 |
| CAPREUR:EO | BBG00H6YQ8H7 |
| CAPREUR:XH | BBG00H6YQ8L2 |
| CAPREUR:XF | BBG00H6YQ8N0 |
| CAPREUR:XE | BBG00H6YQ8Q7 |
| CAPREUR:XJ | BBG00H6YQ8R6 |
| CAPREUR:XL | BBG00H6YQ8S5 |
| CAPREUR:XG | BBG00H6YQ8T4 |
| CAPREUR:XO | BBG00H6YQ8V1 |
| CAPREUR:XS | BBG00H6YQ8Z7 |
| CAPREUR:XA | BBG00H6YQ903 |
| CAPREUR:E1 | BBG00H6YQ912 |
| CAPREUR:XT | BBG00H6YQ921 |
| CAPREUR:XW | BBG00H6YQ930 |
| CAPREUR:XU | BBG00H6YQ949 |
| CAPREUR:XV | BBG00H6YQ958 |
| CAPREUR:EU | BBG00H6YQ985 |
| CAPREUR:XX | BBG00JN8N1N2 |
| CAPRUSD:X2 | BBG00JRQ1GS4 |
| CAPRUSD:XB | BBG00JRQ1GT3 |
| CAPRUSD:XH | BBG00JRQ1GW9 |
| CAPRUSD:XF | BBG00JRQ1GY7 |
| CAPRUSD:XE | BBG00JRQ1H02 |
| CAPRUSD:XJ | BBG00JRQ1H11 |
| CAPRUSD:XL | BBG00JRQ1H20 |
| CAPRUSD:XG | BBG00JRQ1H48 |
| CAPRUSD:XO | BBG00JRQ1H57 |
| CAPRUSD:XS | BBG00JRQ1HB0 |
| CAPRUSD:XA | BBG00JRQ1HC9 |
| CAPRUSD:E1 | BBG00JRQ1HF6 |
| CAPRUSD:XT | BBG00JRQ1HG5 |
| CAPRUSD:XW | BBG00JRQ1HJ2 |
| CAPRUSD:XU | BBG00JRQ1HK0 |
| CAPRUSD:XV | BBG00JRQ1HM8 |
| CAPRUSD:XM | BBG00JRQ1HN7 |
| CAPRUSD:XQ | BBG00JRQ1HR3 |
| CAPRUSD:XX | BBG00JRQ1HT1 |
| CAPRUSD:XZ | BBG00JRQ1HV8 |
| CAPRUSD:EU | BBG00JRQ1J35 |
| CAPRGBX:XS | BBG00L4397V3 |
| CAPRGBX:XH | BBG00L4397Y0 |
| CAPRGBX:XF | BBG00L439805 |
| CAPRGBX:XE | BBG00L439823 |
| CAPRGBX:XJ | BBG00L439832 |
| CAPRGBX:XL | BBG00L439841 |
| CAPRGBX:XG | BBG00L439850 |
| CAPRGBX:XO | BBG00L439869 |
| CAPRGBX:XA | BBG00L4398B3 |
| CAPRGBX:E1 | BBG00L4398C2 |
| CAPRGBX:XT | BBG00L4398D1 |
| CAPRGBX:XW | BBG00L4398F9 |
| CAPRGBX:XU | BBG00L4398G8 |
| CAPRGBX:XV | BBG00L4398H7 |
| CAPRGBX:XM | BBG00L4398J5 |
| CAPRGBX:B1 | BBG00L4398K3 |
| CAPRGBX:XQ | BBG00L4398L2 |
| CAPRGBX:XX | BBG00L4398M1 |
| CAPRGBX:XZ | BBG00L4398N0 |
| CAPRGBX:EU | BBG00L4398R6 |
| 4LN2:TH | BBG00PQBP9G7 |
| 4LN2:GZ | BBG00SVFD0X9 |
| CAPR2EUR:EU | BBG00SVFDRC3 |
| CAPR:VG | BBG00X1N8LB8 |
| CAPR:VP | BBG00X1RQ3S1 |
| CAPRUSD:EP | BBG00XGXD8R6 |
| CAPRUSD:EZ | BBG00XGXD8T4 |
| 4LN2:LA | BBG018H9JBN3 |
| 4LN2:LU | BBG018J35CD8 |
components_SimilarSitesList_0
components_GenericText_2
components_GenericText_3
components_GenericText_4
components_GenericText_6
components_GenericText_8
components_GenericText_9
components_GenericText_11
components_GenericText_13
components_GenericText_14
components_GenericText_17
components_GenericText_19
components_GenericText_21
components_GenericText_23
components_GenericText_25
components_GenericText_26
components_GenericText_29
components_GenericText_31
components_GenericText_33
components_GenericText_34
components_GenericText_36
components_GenericText_38
components_GenericText_39
components_GenericText_42
components_GenericText_44
components_GenericText_46
components_GenericText_48
components_GenericText_50
components_GenericText_52
components_GenericText_53
components_GenericText_55
components_GenericText_57
components_GenericText_59
components_GenericText_61
components_GenericText_63
components_GenericText_65
components_GenericText_66
components_GenericText_68
components_GenericText_70
components_GenericText_72
components_GenericText_74
components_GenericText_76
components_GenericText_78
components_GenericText_79
components_GenericText_81
components_GenericText_83
components_GenericText_85
components_GenericText_87
components_GenericText_89
components_GenericText_91
components_GenericText_92
components_GenericText_94
components_GenericText_96
components_GenericText_98
components_GenericText_100
components_GenericText_102
components_GenericText_104
components_GenericText_106
components_GenericText_108
components_GenericText_109
components_GenericText_111
components_GenericText_113
components_GenericText_115
components_GenericText_117
components_GenericText_119
components_GenericText_121
components_GenericText_123
components_GenericText_125
components_GenericText_127
components_GenericText_129
components_GenericText_131
components_GenericText_133
components_GenericText_134
components_GenericText_136
components_GenericText_157
components_GenericText_159
components_GenericText_160
components_GenericText_162
components_GenericText_177
components_GenericText_179
components_GenericText_181
components_GenericText_183
components_GenericText_184
components_GenericText_186
components_GenericText_187
components_GenericText_189
components_GenericText_191
components_GenericText_193
components_GenericText_195
components_GenericText_197
components_GenericText_198
components_GenericText_201
components_GenericText_202
components_GenericText_205components_GenericText_204
components_GenericText_207components_GenericText_206
components_GenericText_208components_GenericText_209
components_GenericText_211components_GenericText_212
components_GenericText_213components_GenericText_214
components_GenericText_215components_GenericText_216
components_GenericText_219components_GenericText_218
components_GenericText_220components_GenericText_221
components_GenericText_222components_GenericText_223
components_GenericText_224
components_GenericText_225
components_GenericText_228
components_GenericText_229
components_GenericText_231
components_GenericText_233
components_GenericText_235
components_GenericText_237
components_GenericText_239
components_GenericText_240
components_GenericText_241
components_GenericText_243
components_GenericText_244
components_GenericText_246
components_GenericText_249
components_GenericText_251
components_GenericText_253
components_GenericText_254
components_GenericText_256
components_GenericText_257
components_GenericText_259
components_GenericText_261
components_GenericText_263
components_GenericText_265
components_GenericText_267
components_GenericText_269
components_GenericText_270
components_GenericText_273 components_GenericText_274:
components_GenericText_290 components_GenericText_291:
components_GenericText_301
components_Profile_KeyStats__35
